G-Csf has 3 known drug interactions based on U.S. FDA drug labeling data. Of these, 1 are contraindicated combinations that should be avoided entirely. 2 are classified as major interactions requiring close medical supervision. Notable interactions include combinations with Exagamglogene Autotemcel, Cyclophosphamide, Topotecan. Patients taking G-Csf should inform their healthcare provider of all current medications — including over-the-counter drugs and supplements — to avoid potentially harmful combinations. Data sourced from OpenFDA and the NIH National Library of Medicine.
- Total
- 3
- Contraindicated
- 1
- Major
- 2
Contraindicated (1)
- G-Csf + Exagamglogene Autotemcel— G-CSF must not be used for CD34+ HSC mobilization in patients with SCD.
Major (2)
- G-Csf + Cyclophosphamide— Reports suggest increased risk of pulmonary toxicity in patients treated with cyclophosphamide and G-CSF.
- G-Csf + Topotecan— Concomitant administration can prolong the duration of neutropenia. Do not initiate G-CSF until day 6 of topotecan thera…